Cangene gets OK for hepatitis B therapy

Canada's Cangene has received FDA approval for HepaGam B, a treatment for hepatitis B. Cangene says it expects to start marketing the drug in the next few months. Some 2 billion people have been infected with the hepatitis B virus. "This is Cangene's fourth approved drug and the third drug to receive FDA approval--a significant accomplishment for a biopharmaceutical company," said Dr. John Langstaff, Cangene's president and CEO.

- read this release for more information

Suggested Articles

NGM's aldafermin beat placebo at reversing liver scarring and inflammation, as well as reducing liver fat buildup in a 78-patient study.

The agreement sees Grifols waive a $32 million debt and pay $3 million in cash to take full ownership of three assets.

Astellas’ Xospata and Novartis’ Rydapt may help treat lung cancer that has grown resistant to EGFR inhibitors, researchers discovered.